Precision BioSciences Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Hello, everyone, and good afternoon, and welcome back to H.C. Wainwright's 24th Annual Global Investment Hybrid Conference. My name is Patrick Trucchio. I'm a senior healthcare analyst at H.C. Wainwright.
It's my pleasure to introduce our next presenter. I'd like to welcome Michael Amoroso, CEO; Derek Jantz, CSO; and Alan List, CMO of Precision BioSciences, a clinical-stage gene-editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies.
So maybe if we could just begin with an overview of Precision's ARCUS platform, how it's differentiated versus other approaches in the field such as CRISPR.
Yes, just a quick one, Patrick. And Wainwright, thanks for having us. We're excited to be with you. And I'm going to turn it over to our CSO and Co-Founder, Derek Jantz, for an overview on the organization.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
